Immunosafety of recombinant human C1-inhibitor in hereditary angioedema: Evaluation of IgE antibodies

Clinical Drug Investigation

Volumn 33, Issue 4, 2013, Pages 275-281

  Hack, C Erik ^a   Relan, Anurag ^b   Baboeram, Aartie ^b   Oortwijn, Beatrijs ^b   Versteeg, Serge ^c   Van Ree, Ronald ^c   Pijpstra, Rienk ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Pharming Group NV   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; COMPLEMENT COMPONENT C1S INHIBITOR; IMMUNOGLOBULIN E ANTIBODY; PLACEBO;

ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EPITHELIUM; FEMALE; HUMAN; IMMUNE FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MILK; MULTICENTER STUDY; PRIORITY JOURNAL; RABBIT; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION;

ANAPHYLAXIS; ANGIOEDEMAS, HEREDITARY; CASE-CONTROL STUDIES; COMPLEMENT C1 INHIBITOR PROTEIN; HUMANS; IMMUNOGLOBULIN E; RECOMBINANT PROTEINS;

EID: 84877039218     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0064-2     Document Type: Article

References (13)

1. Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010;126:821-7.
2. Davis B, Bernstein JA. Conestat alfa for the treatment of angioedema attacks. Ther Clin Risk Manag. 2011;7:265-73.
3. Varga L, Farkas H. RhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency. Expert Rev Clin Immunol. 2011;7:143-53.
4. Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(suppl):S51-131.
5. Jahn EM, Schneider CK. How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations. N Biotechnol. 2009;25:280-6.
6. Schellekens H. The immunogenicity of therapeutic proteins. Discov Med. 2010;9:560-4.
7. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117:391-7.
8. Kobayashi K. Summary of recombinant human serum albumin development. Biologicals. 2006;34:55-9.
9. van Doorn MB, Burggraaf J, van Dam T, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol. 2005;116:876-83.
10. Choi G, Soeters MR, Farkas H, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion. 2007;47:1028-32.
11. Restani P, Gaiaschi A, Plebani A, et al. Cross-reactivity between milk proteins from different animal species. Clin Exp Allergy. 1999;29:997-1004.
12. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. 2008;359:1027-36.
13. Hack CE, Relan A, Baboeram A, et al. Immunogenicity assessment of recombinant human C1-inhibitor: an integrated analysis of clinical studies. Accepted for publication by BioDrugs on 08 May 12.